Pay attention to the value of liver regeneration in the re-compensation of decompensated cirrhosis
- PMID: 40599187
- PMCID: PMC12207540
- DOI: 10.3748/wjg.v31.i24.106564
Pay attention to the value of liver regeneration in the re-compensation of decompensated cirrhosis
Abstract
Conventional wisdom holds that progression from compensated cirrhosis to decompensated cirrhosis is irreversible in the natural history of the disease. However, in recent years, more and more clinical evidence suggests that liver cirrhosis can achieve re-compensation, that is, after effective etiological treatment and complication management, the liver function of partially decompensated patients with cirrhosis has improved and gradually stabilized, and decompensation no longer occurs for a long time. Liver regeneration, as one of the powerful intrinsic abilities of the liver, is the key to the restoration of the structure and complex physiological functions of the damaged liver. Studies have shown that the restoration of liver regeneration in patients with cirrhosis can promote the occurrence of re-compensation, thereby improving the prognosis of patients. At the same time, monitoring liver regeneration indicators is helpful in assessing patients' re-compensation potential for early selection of appropriate treatment options. Insufficient attention has been paid to the role of liver regeneration in the course of liver cirrhosis. Therefore, this article aims to review the value of liver regeneration in the re-compensation of decompensated cirrhosis.
Keywords: Decompensated cirrhosis; Liver regeneration; Prognosis; Re-compensation; α-fetoprotein.
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors do not choose to declare any conflict of interest related directly or indirectly to the subject of this article.
Figures
Similar articles
-
Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.Cochrane Database Syst Rev. 2023 Jun 6;6(6):CD013532. doi: 10.1002/14651858.CD013532.pub2. Cochrane Database Syst Rev. 2023. PMID: 37278488 Free PMC article.
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714
-
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease.Cochrane Database Syst Rev. 2016 Mar 2;3(3):CD011602. doi: 10.1002/14651858.CD011602.pub2. Cochrane Database Syst Rev. 2016. PMID: 26934429 Free PMC article.
-
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080. Health Technol Assess. 2006. PMID: 16545207
-
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.Health Technol Assess. 2007 Sep;11(34):1-206. doi: 10.3310/hta11340. Health Technol Assess. 2007. PMID: 17767898
References
-
- Emenena I, Emenena B, Kweki AG, Aiwuyo HO, Osarenkhoe JO, Iloeje UN, Ilerhunmwuwa N, Torere BE, Akinti O, Akere A, Casimir OE. Model for End Stage Liver Disease (MELD) Score: A Tool for Prognosis and Prediction of Mortality in Patients With Decompensated Liver Cirrhosis. Cureus. 2023;15:e39267. - PMC - PubMed
-
- Tsai FJ, Yang PY, Chen CJ, Li JP, Li TM, Chiou JS, Cheng CF, Chuang PH, Lin TH, Liao CC, Huang SM, Ban B, Liang WM, Lin YJ. Decreased overall mortality rate with Chinese herbal medicine usage in patients with decompensated liver cirrhosis in Taiwan. BMC Complement Med Ther. 2020;20:221. - PMC - PubMed
-
- Chandna S, Zarate ER, Gallegos-Orozco JF. Management of Decompensated Cirrhosis and Associated Syndromes. Surg Clin North Am. 2022;102:117–137. - PubMed
-
- Premkumar M, Dhiman RK, Duseja A, Mehtani R, Taneja S, Gupta E, Gupta P, Sandhu A, Sharma P, Rathi S, Verma N, Kulkarni AV, Bhujade H, Chaluvashetty SB, Kalra N, Grover GS, Nain J, Reddy KR. Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program. Gastroenterology. 2024;167:1429–1445. - PubMed
-
- Wang Q, Zhao H, Deng Y, Zheng H, Xiang H, Nan Y, Hu J, Meng Q, Xu X, Fang J, Xu J, Wang X, You H, Pan CQ, Xie W, Jia J. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol. 2022;77:1564–1572. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical